ATPW
KRYS icon

Ashton Thomas Private Wealth’s Krystal Biotech KRYS Stock Holding History

Ashton Thomas Private Wealth’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-38
Closed -$6.98K – 1276
2024
Q2 		$6.98K Buy
+38
New +$6.38K ﹤0.01% 1443

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ashton Thomas Private Wealth's KRYS Position: Q3 2024 in Review

Ashton Thomas Private Wealth sold out of Krystal Biotech (KRYS) in Q3 2024, closing a stake of 38 shares — an estimated $6.98K sold.

Ashton Thomas Private Wealth first reported a position in KRYS in Q2 2024 and held it in 1 quarter. The position peaked at $6.98K in Q2 2024. 283 funds tracked by Wall St. Rank hold KRYS as of Q3 2024.

  • Ashton Thomas Private Wealth reported no remaining Krystal Biotech position as of Q3 2024 after selling out during the quarter.
  • Ashton Thomas Private Wealth sold 38 Krystal Biotech shares in Q3 2024, an estimated $6.98K.
  • Ashton Thomas Private Wealth first reported a position in Krystal Biotech in Q2 2024 and held it in 1 quarter.
  • Ashton Thomas Private Wealth's Krystal Biotech position peaked at $6.98K in Q2 2024.
  • 283 funds tracked by Wall St. Rank held Krystal Biotech as of Q3 2024.

Based on Ashton Thomas Private Wealth's 13F filing for Q3 2024, filed 5 Nov 2024.